Pacira Pharmaceuticals, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Serge Belanger from Needham maintained a Buy rating on the stock and has a $30.00 price target.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Serge Belanger has given his Buy rating due to a combination of factors that suggest potential growth for Pacira Pharmaceuticals. Despite the recent underperformance in Exparel sales, which fell short of market expectations for the second consecutive quarter, Belanger sees promising signs for future growth. The company’s narrowed revenue guidance for 2025 and the anticipated positive impact of the NOPAIN initiative in the second half of 2025 are key considerations.
Additionally, the new co-promotion partnership with J&J MedTech for Zilretta is expected to contribute to sales growth. Furthermore, Pacira Pharmaceuticals has a substantial amount remaining in its share repurchase program, which could provide additional value to shareholders. These elements combined form the basis of Belanger’s optimistic outlook and Buy rating for the stock.
In another report released on July 25, Truist Financial also upgraded the stock to a Buy with a $30.00 price target.